Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

Seoul National University

Status: Completed

Conditions: Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle; Polyp Endometrium; Myoma;Uterus

Treatments: Drug: Remimazolam

Study type: Observational

Funder types: Other

Identifiers

NCT05025410

B-2109-706-301

Details and patient eligibility

About

Remimazolam is a novel drug approved for induction and maintenance of general anesthesia. This study aims to check the appropriate dose and patient response by administering remimazolam and remifentanil in surgery that does not require a neuromuscular blocking agents.

Enrollment: 38 patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult woman scheduled for gynecological surgery under general anesthesia
• American Society of Anesthesiology grade 1 or 2
• When using a laryngeal mask airway to maintain general anesthesia

Exclusion criteria

• Underlying diseases: liver, kidney, brain nervous system, glaucoma
• Patients with BMI greater than 30 and less than 18.5
• Patients diagnosed with sleep apnea
• Alcohol or drug dependent patients
• Patients with severe or acute respiratory failure
• Lactose intolerance
• Dextran 40 hypersensitivity
• Patients in shock or coma

Trial design

38 participants in 1 patient group

General anesthesia using remimazolam and remifentanil

Description:

Adult female patients scheduled for gynecological surgery under general anesthesia using remimazolam and remifentanil

Treatment:

Drug: Remimazolam